Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Rank in Stocks #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicelโ€”a specialized cell therapyโ€”has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Share Price
$0.0327
Last synced: 2025-06-17
Market Cap
$4.34M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
IL
Trade Gamida Cell Ltd. (GMDA)

Category

Stock price history for Gamida Cell Ltd. (GMDA)
Highest end of day price: $0.03 on 2025-06-01

Lowest end of day price: $9.40 on 2018-10-01
Stock price history of Gamida Cell Ltd. from 2018 to 2026
Annual Stock Price Performance
Year Performance
2025 117.76%
2024 -95.28%
2023 -75.22%
2022 -48.32%
2021 -71.87%
2020 84.95%
2019 -55.53%
2018 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE